Erasca Q1 2023 net loss $33.2M; cash $390M; pipeline advances with Phase 3 trial plan

Erasca, Inc.

2023-Q1 EPS reported -$0.22

Net loss $33.2M ($0.22/share) vs $36.5M ($0.31/share) year ago; R&D $27.6M, G&A $9.4M.
Cash, equivalents & marketable securities $389.7M at March 31, 2023, expected to fund into H2 2025.
Pivotal Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma expected to initiate in H1 2024.
FDA Fast Track Designation granted for ERAS-801 in glioblastoma; Phase 1 data expected H2 2023.
Promoted Shannon Morris to CMO and Chandra Lovejoy to Chief Regulatory Affairs Officer in April 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Erasca, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, Erasca, Inc. announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-022194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.